The goal of this study is to learn if circulating tumor DNA and other tumor-related molecules/chemicals released in the blood can help doctors predict if colorectal cancer may come back or spread.

Are you undergoing treatment for a blood cancer diagnosis and experiencing poor sleep?Researchers at the Mays Cancer Center are seeking US-based adults diagnosed with blood cancer and experiencing sleep disturbance to participate in a 20-week remote study testing a digital wellness intervention. Participants in this study will be assigned to use one of two digital wellness apps 10 minutes per day over 8-weeks to determine if it can help improve sleep, immune function, and other psychological and emotional outcomes.This study is completely remote (there are no in-person visits with the research team) and patients from across the USA are invited.Participation involves:One brief 30-minute virtual meeting with a research assistantCompleting online surveysProviding three blood samples over the 20-week study at a lab close to youTracking sleep using a small device and daily diaryUsing a wellness app for 10 minutes per day for 8-weeksParticipants who qualify and are enrolled in the study will be compensated at regular intervals, up to $100 total.

This research is being done to see if an investigational blood test can predict whether cancer will recur (come back) after initial treatment

This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy or radiation therapy.

This phase I trial studies the side effects and best dose of pembrolizumab and recombinant interleukin-12 in treating patients with solid tumors. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Recombinant interleukin-12 may kill tumor cells by blocking blood flow to the tumor and by stimulating white blood cells to kill tumor cells. Giving pembrolizumab and recombinant interleukin-12 may work better than giving pembrolizumab alone in treating patients with solid tumors.

This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications.

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.